A Melbourne-based skincare startup approached us after trying unsuccessfully to match the performance and stability profile of a viral niacinamide-based brightening cream. Despite achieving similar textures and colors, their lab samples lacked the same visible skin tone improvements as the product setting the market standard. The challenge was compounded by the fact that the benchmark formula contained several undisclosed actives and complex emulsifiers. The client’s in-house team lacked the tools and expertise to conduct advanced compositional analysis effectively.

• The presence of overlapping whitening agents (niacinamide, arbutin, thiamidol), making dosage estimation complex.

• Chiral forms of actives not clearly labeled (e.g., α-arbutin vs β-arbutin).

• Use of unlisted emulsifier blends that influenced absorption and spreadability.

• Poor performance in benchmark batches despite similar ingredient lists.

We initiated a multi-step analytical and formulation remediation project:

• Fingerprint analysis using LC-MS and chiral HPLC to differentiate between α-arbutin and β-arbutin.

• Matched the Ceteareth-20 emulsifier by confirming the ethoxylation degree via FTIR and NMR.

• Identified the optimal emulsifier-surfactant ratios to stabilize thiamidol in low-pH environments.

• Provided detailed ingredient substitution guidance using verified local suppliers for cost-effective sourcing.

The client achieved the brightening efficacy target within 8 weeks, launching a successful lab-scale pilot. Follow-up trials showed the same efficacy and better consumer feedback on texture and scent, validating their R&D performance goals.